Press Release: Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
Novartis International AG / Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study . Processed and transmitted by Nasdaq Corpo… FinanzNachrichten.de: Aktuelle...
